Antonio Luis Valero Santiago-rekin lankidetzan egindako argitalpenak (40)

2022

  1. Consensus on the Definition of Control and Remission in Chronic Urticaria

    Journal of Investigational Allergology and Clinical Immunology, Vol. 32, Núm. 4, pp. 261-269

  2. Daily Clinical Practice in the Management of Chronic Urticaria in Spain: Results of the UCREX Study

    Actas Dermo-Sifiliograficas, Vol. 113, Núm. 1, pp. T4-T14

2019

  1. Psychometric properties of the Spanish version of the once-daily Urticaria Activity Score (UAS) in patients with chronic spontaneous urticaria managed in clinical practice (the EVALUAS study)

    Health and Quality of Life Outcomes, Vol. 17, Núm. 1

  2. Therapeutic strategy according to differences in response to omalizumab in patients with chronic spontaneous urticaria giménez

    Journal of Investigational Allergology and Clinical Immunology, Vol. 29, Núm. 5, pp. 338-348

2017

  1. Allergic rhinitis severity can be assessed using a visual analogue scale in mild, moderate and severe

    Rhinology, Vol. 55, Núm. 1, pp. 34-38

  2. Allergy rhinitis: Similarities and differences between children and adults

    Rhinology, Vol. 55, Núm. 4, pp. 326-331

  3. Management of chronic spontaneous urticaria in routine clinical practice: A Delphi-method questionnaire among specialists to test agreement with current European guidelines statements

    Allergologia et Immunopathologia, Vol. 45, Núm. 2, pp. 134-144

  4. Omalizumab efficacy in cases of chronic spontaneous urticaria is not explained by the inhibition of sera activity in effector cells

    Scientific Reports, Vol. 7, Núm. 1

2016

  1. Allergic rhinitis causes loss of smell in children: The OLFAPEDRIAL study

    Pediatric Allergy and Immunology, Vol. 27, Núm. 8, pp. 867-870

  2. Comparable actions of omalizumab on mast cells and basophils

    Clinical and Experimental Allergy, Vol. 46, Núm. 1, pp. 92-102

2015

  1. Management of urticaria: Not too complicated, not too simple

    Clinical and Experimental Allergy, Vol. 45, Núm. 4, pp. 731-743

2014

  1. Assessment of severity and quality of life in chronic urticaria

    Journal of Investigational Allergology and Clinical Immunology, Vol. 24, Núm. 2, pp. 80-86

2013

  1. Analysis of comorbidities and therapeutic approach for allergic rhinitis in a pediatric population in Spain

    Pediatric Allergy and Immunology, Vol. 24, Núm. 7, pp. 678-684

  2. Antihistamines in drivers, aircrew and occupations of risk.

    Journal of investigational allergology & clinical immunology, Vol. 23 Suppl 1, pp. 27-34

  3. Bilastine for the treatment of urticaria

    Expert Opinion on Pharmacotherapy, Vol. 14, Núm. 11, pp. 1537-1544

  4. ESPRINT-15 questionnaire (Spanish version): Reference values according to disease severity using both the original and the modified ARIA classifications

    Journal of Investigational Allergology and Clinical Immunology, Vol. 23, Núm. 1, pp. 14-19

  5. Efficacy of omalizumab in chronic spontaneous urticaria refractory to conventional therapy: Analysis of 110 patients in real-life practice

    Expert Opinion on Biological Therapy, Vol. 13, Núm. 9, pp. 1225-1228

  6. H1 antihistamines and benzodiazepines. Pharmacological interactions and their impact on cerebral function.

    Journal of investigational allergology & clinical immunology, Vol. 23 Suppl 1, pp. 17-26

  7. Use of second generation H1 antihistamines in special situations.

    Journal of investigational allergology & clinical immunology, Vol. 23 Suppl 1, pp. 1-16

2012

  1. Validation of the modified allergic rhinitis and its impact on asthma (ARIA) severity classification in allergic rhinitis children: The PEDRIAL study

    Allergy: European Journal of Allergy and Clinical Immunology, Vol. 67, Núm. 11, pp. 1437-1442